Anika Therapeutics, Inc.
ANIK · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $113M | $120M | −5.9% |
| Operating income | −$11.1M | −$5.10M | −117% |
| Net income | −$10.9M | −$56.4M | +80.7% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 6, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $30.6M | $27.8M | +10.1% |
| Operating income | −$700K | −$3.20M | +78.1% |
| Net income | −$300K | −$2.30M | +87.0% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Anika Therapeutics's revenue in FY2025?
- $113M in FY2025 (Fiscal year ended Dec 31, 2025), −5.9% vs $120M a year earlier, per its 10-K filed Mar 2026.
- Was Anika Therapeutics profitable in FY2025?
- No: net income was −$10.9M and operating income −$11.1M in FY2025.
- What was Anika Therapeutics's revenue in Q3 2026?
- $30.6M (+10.1% vs a year earlier), per its Form 10-Q filed Nov 6, 2026.